Sisram Medical Bundle
Who owns Sisram Medical?
Sisram Medical's ownership story began in 2013 with Fosun Pharma's acquisition of Alma Lasers. This move established Sisram Medical as an investment holding company focused on energy-based medical aesthetics.
Founded with a vision for global leadership in medical technology, Sisram Medical has evolved into a significant player in the consumer wellness sector, leveraging over two decades of experience in medical aesthetics.
As of July 18, 2025, Sisram Medical has a market capitalization of $266 million and 468 million shares outstanding. The company's product development spans laser, light-based, radiofrequency, and ultrasound technologies, serving medical professionals worldwide for various aesthetic and medical applications, including those analyzed in a Sisram Medical Porter's Five Forces Analysis.
Who Founded Sisram Medical?
Sisram Medical Ltd. was incorporated in Israel on April 25, 2013, not through individual founders but as an investment vehicle. Its primary purpose was to facilitate the acquisition of Alma Lasers Ltd. by Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma).
Inception as an Acquisition VehicleSisram Medical was established in 2013 specifically to acquire Alma Lasers. This strategic move was orchestrated by Fosun Pharma.
Fosun Pharma's Controlling StakeFosun Pharma acquired a significant 96% stake in Alma Lasers in 2013 for $240 million. This acquisition formed the bedrock of Sisram Medical's early ownership structure.
Alma Lasers' Pre-Sisram HistoryBefore Sisram Medical's formation, Alma Lasers had experienced private equity investment. TA Associates gained control in 2006, valuing the company at $150 million.
Leadership and VisionLior Dayan currently serves as the CEO for both Sisram Medical and Alma Lasers. The overarching vision, driven by Fosun Pharma, aimed to build an integrated consumer-focused ecosystem leveraging Alma's expertise.
Strategic ObjectiveThe strategic goal was to transform Alma Lasers into a global wellness consumer brand. This involved integrating its leadership in energy-based medical aesthetics.
Principal Operating SubsidiaryAlma Lasers became the principal operating subsidiary of Sisram Medical following the acquisition. This established a clear corporate structure from the outset. |
The early ownership of Sisram Medical is fundamentally tied to Fosun Pharma's substantial investment and control, established at the time of its incorporation. This strategic acquisition of Alma Lasers by Fosun Pharma positioned Sisram Medical as a key entity within Fosun's broader healthcare ambitions, aiming to create a comprehensive consumer wellness brand.
Key Aspects of Early Ownership
Sisram Medical's inception was driven by a strategic acquisition rather than traditional founding. Fosun Pharma's acquisition of Alma Lasers in 2013 for $240 million, securing a 96% stake, defined its initial ownership structure.
- Sisram Medical was incorporated on April 25, 2013, in Israel.
- The company was established as an investment holding entity.
- Its primary purpose was the acquisition of Alma Lasers Ltd.
- Fosun Pharma is the controlling shareholder, holding 96% of Alma Lasers.
- Alma Lasers operates as the principal operating subsidiary of Sisram Medical.
- The vision for Sisram Medical was to build a global wellness consumer brand.
Sisram Medical SWOT Analysis
- Complete SWOT Breakdown
- Fully Customizable
- Editable in Excel & Word
- Professional Formatting
- Investor-Ready Format
How Has Sisram Medical’s Ownership Changed Over Time?
The ownership journey of Sisram Medical began with its acquisition by Fosun Pharma in 2013, evolving into a publicly listed entity on the Hong Kong Stock Exchange in 2017. This transition marked a significant shift in its corporate structure and investor base.
| Event | Date | Impact on Ownership |
| Acquisition of Alma Lasers by Fosun Pharma | 2013 | Sisram Medical became a non-wholly owned subsidiary of Fosun Pharma. |
| Initial Public Offering (IPO) on HKEX | September 19, 2017 | Raised $112 million; Fosun Pharma held a 66% stake post-IPO. |
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma) remains the primary majority owner of Sisram Medical, underscoring its substantial influence over the company's strategic direction. Fosun Pharma itself is a subsidiary of Fosun International Holdings Limited, with Mr. Guo Guangchang identified as the ultimate controlling shareholder. The company's stock performance is reflected in its market capitalization, which stood at $266 million as of July 18, 2025, with 468 million shares in circulation. This ownership structure is crucial for understanding the Target Market of Sisram Medical and its operational framework.
Key Stakeholders in Sisram Medical
Understanding who owns Sisram Medical is key to grasping its corporate governance and future trajectory. Fosun Pharma's majority ownership significantly shapes its business operations.
- Majority Owner: Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma)
- Ultimate Controlling Shareholder: Mr. Guo Guangchang
- Publicly Traded: Hong Kong Stock Exchange (HKEX: 1696.HK)
- Other Investors: Including HuaAn Fund Management Co., Ltd.
Sisram Medical PESTLE Analysis
- Covers All 6 PESTLE Categories
- No Research Needed – Save Hours of Work
- Built by Experts, Trusted by Consultants
- Instant Download, Ready to Use
- 100% Editable, Fully Customizable
Who Sits on Sisram Medical’s Board?
The board of directors for Sisram Medical is structured to reflect its ownership, with key leadership roles held by individuals connected to its primary shareholder. Liu Yi chairs the board, and Lior Dayan serves as the CEO and an Executive Director. While specific affiliations for all board members are not detailed, the significant ownership by the parent company suggests their nominees are present to align with strategic goals.
| Board Position | Name | Affiliation (Implied/Known) |
| Chairman | Liu Yi | Linked to major shareholder |
| CEO & Executive Director | Lior Dayan | Executive Management |
As a company listed on the HKEX, Sisram Medical typically follows a one-share-one-vote system. However, the majority ownership of 66% by Fosun Pharma at the time of its IPO grants them considerable voting power. A 2017 prospectus indicated a 'Voting Agreement' that would have Fosun Pharma subsidiaries vote in alignment if their direct or indirect interest dropped below 50%. Since Fosun Pharma's interest remained above this threshold post-IPO, this specific agreement was not activated. The absence of recent proxy fights or activist campaigns suggests that Fosun Pharma's controlling stake provides a stable governance framework for the company's decisions.
Understanding Sisram Medical's Voting Power
Fosun Pharma's majority ownership significantly influences Sisram Medical's corporate governance. This control impacts strategic decisions and board composition.
- One-share-one-vote principle generally applies.
- Fosun Pharma held 66% of shares at IPO, ensuring majority control.
- No recent proxy battles indicate stable governance.
- The Competitors Landscape of Sisram Medical is influenced by its strategic direction.
Sisram Medical Business Model Canvas
- Complete 9-Block Business Model Canvas
- Effortlessly Communicate Your Business Strategy
- Investor-Ready BMC Format
- 100% Editable and Customizable
- Clear and Structured Layout
What Recent Changes Have Shaped Sisram Medical’s Ownership Landscape?
Over the past few years, Sisram Medical has maintained a stable ownership structure, with Fosun Pharma holding the majority control. Recent strategic moves have focused on expanding direct sales and product offerings rather than significant ownership shifts.
| Financial Year | Revenue (US$) | Net Profit (US$) | Gross Profit Margin | Direct Sales Revenue % |
|---|---|---|---|---|
| 2023 | 359.3 million | 32.9 million | 61.1% | 78% |
| 2024 | 349.1 million | 28.8 million | 62.1% | 87% |
Sisram Medical's recent developments highlight a strategic push towards strengthening its direct market presence and enhancing its product portfolio. The company has focused on organic growth, with Fosun Pharma continuing to provide support, indicating a consistent long-term ownership outlook.
Direct Sales Expansion
The company significantly increased its direct sales revenue to 87% in 2024, up from 78% in 2023. This focus on direct channels is a key driver for its business operations.
Product Portfolio Growth
Sisram Medical has expanded its injectables line through partnerships and secured approvals for new products. The launch of Alma Harmony™ in the U.S. in H1 2024 further bolsters its offerings.
Strategic Acquisitions
In July 2023, Sisram Medical's subsidiary Alma acquired PhotonMed International Ltd. This acquisition aimed to establish direct operations in mainland China, reinforcing its global presence.
Financial Performance Overview
For the year ended December 31, 2024, Sisram Medical reported revenues of US$349.1 million, a slight decrease from the previous year. Despite this, the gross profit margin improved to 62.1%.
Sisram Medical Porter's Five Forces Analysis
- Covers All 5 Competitive Forces in Detail
- Structured for Consultants, Students, and Founders
- 100% Editable in Microsoft Word & Excel
- Instant Digital Download – Use Immediately
- Compatible with Mac & PC – Fully Unlocked
- What is Brief History of Sisram Medical Company?
- What is Competitive Landscape of Sisram Medical Company?
- What is Growth Strategy and Future Prospects of Sisram Medical Company?
- How Does Sisram Medical Company Work?
- What is Sales and Marketing Strategy of Sisram Medical Company?
- What are Mission Vision & Core Values of Sisram Medical Company?
- What is Customer Demographics and Target Market of Sisram Medical Company?
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.